Clinical Trial Update: A Study To Determine Any Effect Of Tafamidis On Electrocardiographic Intervals, Specifically The Rate Corrected QT Interval (QTc) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating whether tafamidis affects QTc intervals in transthyretin amyloid cardiomyopathy. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin Amyloid Cardiomyopathy

Drugs mentioned

• Vyndamax (tafamidis)

Snippet

Sponsor: Pfizer | Conditions: TTR Cardiomyopathy | Phase 1 | Status: COMPLETED